Core Viewpoint - The company reported a significant decline in revenue and an increase in net losses for the third quarter of 2025, indicating ongoing financial challenges and the need for strategic transformation [1] Financial Performance - For the third quarter, the company's revenue was 274 million, a year-on-year decrease of 38.4% [1] - The net loss for the third quarter improved slightly to 31.12 million from a loss of 51.25 million in the same period last year [1] - Year-to-date revenue for 2025 was 857 million, down 39.6% compared to the previous year [1] - The net loss for the year-to-date period increased to 87.24 million from a loss of 56.03 million in the previous year [1] - Total assets as of the end of the third quarter were 2.09 billion, a decrease of 26.1% from the end of the previous year [1] - The company's net assets increased by 16.8% to 1.091 billion compared to the end of the previous year [1] Strategic Focus - The company is focusing on core business areas and optimizing its operational structure while undergoing a strategic transformation towards medical intelligence [1] - The decline in revenue and gross profit was attributed to the transfer of equity in some subsidiaries during the reporting period [1] - To enhance profitability, the company has strengthened cost control, resulting in a combined reduction of 18.54% in sales, management, and financial expenses [1] - The report indicated that the company recognized credit impairment losses, which impacted operating profits [1] Business Operations - The company's main business includes medical supply chain services and the research and sales of related products, aiming to provide efficient medical services and solutions to clients [1] - The company plans to continue optimizing its business structure and upgrading its operations to respond to market changes and industry challenges [1]

Core Viewpoint - The financial performance of Sely Medical (603716) has significantly declined in the first three quarters of 2025, with a notable drop in both revenue and net profit, leading to a negative outlook for the company [1][3]. Trading Information Summary - On October 29, 2025, Sely Medical's stock closed at 24.3 yuan, down 0.25%, with a turnover rate of 4.51% and a trading volume of 94,700 shares, resulting in a transaction amount of 230 million yuan [1]. - The main funds experienced a net outflow of 38.52 million yuan, accounting for 16.77% of the total transaction amount, while retail investors saw a net inflow of 48.24 million yuan, representing 21.01% of the total [1][3]. Financial Report Summary - For the first three quarters of 2025, Sely Medical reported a main revenue of 857 million yuan, a year-on-year decrease of 39.64%, and a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [1]. - In Q3 2025, the company recorded a single-quarter main revenue of 274 million yuan, a decline of 38.41% year-on-year, and a net profit of -31.12 million yuan, which is an increase of 39.27% compared to the previous quarter [1]. - The company’s debt ratio stands at 49.61%, with investment income of 7.34 million yuan and financial expenses of 349.82 million yuan, resulting in a gross profit margin of 21.73% [1]. Company Announcement Summary - On October 29, 2025, Sely Medical held the 22nd meeting of the fifth board of directors, where all nine directors were present, and no votes were against or abstained [2]. - The board approved the Q3 2025 report and the proposal for asset impairment preparation, both of which had been previously reviewed by the audit committee [2][3].

Group 1 - The company, Saily Medical, announced a credit impairment loss of 20.713 million yuan and an asset impairment loss of 760,800 yuan for the first three quarters of 2025, totaling 21.4738 million yuan, which will reduce the total profit for the same period by the same amount [1] - The impairment provisions made by the company have not been audited by an accounting firm, and the impact on the annual profit for 2025 will be determined based on the results of the annual audit [1] - For the year 2024, the company's revenue composition is 97.09% from commercial activities and 2.91% from industrial activities [1] Group 2 - As of the latest report, Saily Medical has a market capitalization of 5.1 billion yuan [2]

Group 1 - The core point of the article is that Saily Medical reported a significant decline in revenue and incurred a net loss in the third quarter of 2023 [1] Group 2 - For the first three quarters of 2025, the company's revenue was approximately 857 million yuan, representing a year-on-year decrease of 39.64% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 87.24 million yuan [1] - The basic earnings per share showed a loss of 0.44 yuan [1] - As of the report date, Saily Medical's market capitalization was 5.1 billion yuan [2]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the third quarter of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 857 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 39.64% [1] - The net profit attributable to shareholders of the parent company was -87.2441 million yuan, which is a deterioration of 31.219 million yuan compared to the same period last year [1] - The basic earnings per share were -0.44 yuan [1]

| | | 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《公 司法》等相关法律法规和《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： 塞力斯医疗科技集团股份有限公司 第五届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年 10 月 24 日以邮件方式发送第五届董事会第二十二次会议通知，会议于 2025 年 10 月 29 日在公司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应到董事 9 人，实到董事 9 人，会议由董事长温伟先生主持，公司全部高级管理人员列席了 会议。 （二）审议通过《关于 2025 年前三季度计提资产减值准备的议案》 本议案已经第五届董事会审计委员会 2025 年第三次会议审议通过，并同意 提交董事会审议。 具体内容详见刊登在上海证券交易所网站（www.sse.com.cn）上的《关于 2025 ...

Financial Performance - The company's revenue for Q3 2025 was approximately ¥273.70 million, representing a decrease of 38.41% compared to the same period last year[4]. - The total profit for the period was a loss of ¥28.43 million, with a net profit attributable to shareholders of ¥31.12 million, indicating significant financial challenges[4]. - For the first nine months of 2025, the company reported a total revenue of ¥857.21 million, down 39.64% year-on-year, with a net loss of ¥87.24 million[6]. - Total revenue for the first three quarters of 2025 was ¥857,205,461.50, a decrease of 39.7% compared to ¥1,420,111,454.42 in the same period of 2024[23]. - Net loss for the first three quarters of 2025 was ¥79,153,203.33, compared to a net loss of ¥33,512,646.83 in 2024, representing a 135.7% increase in losses[24]. - Operating profit for the first three quarters of 2025 was -¥80,483,168.62, worsening from -¥50,183,819.91 in the same period of 2024[24]. - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.44, compared to -¥0.28 in 2024[25]. Revenue Decline Factors - The company attributed the revenue decline to the transfer of certain subsidiaries and a strategic shift towards optimizing its business structure[6]. - The company is focusing on transforming its traditional medical supply chain services towards medical intelligence, which has impacted revenue and profit margins[6]. Cash Flow and Expenses - Cash flow from operating activities showed a net inflow of ¥54.57 million, reflecting a decrease in cash received from sales and services[5]. - The company has implemented cost control measures, resulting in a reduction of sales, management, and financial expenses by ¥50 million, or 18.54% year-on-year[7]. - In the first three quarters of 2025, the cash inflow from operating activities was CNY 998,060,771.28, a decrease of 38.0% compared to CNY 1,608,884,916.58 in the same period of 2024[27]. - The net cash flow from operating activities was negative at CNY -24,599,514.16, compared to a positive CNY 496,140.58 in the first three quarters of 2024[27]. - The company reported a total cash outflow from operating activities of CNY 1,022,660,285.44, compared to CNY 1,608,388,776.00 in the previous year[27]. Asset and Equity Changes - The total assets at the end of the reporting period were approximately ¥2.09 billion, a decrease of 26.14% from the previous year[5]. - The equity attributable to shareholders increased by 16.78% to ¥1.09 billion compared to the end of the previous year[5]. - Total assets decreased from ¥2,830,070,456.98 in the previous period to ¥2,090,356,280.83, a decline of 26.2%[21]. - The company's equity increased from ¥962,044,094.58 to ¥1,053,305,930.21, an increase of 9.5%[21]. Current Assets and Liabilities - The company reported a total current assets of RMB 1,381,721,482.71 as of September 30, 2025, a decrease of approximately 33.8% from RMB 2,087,128,419.96 on December 31, 2024[19]. - Cash and cash equivalents decreased to RMB 139,610,238.67 from RMB 209,435,589.90, representing a decline of about 33.3%[19]. - Accounts receivable fell to RMB 834,694,092.99, down 35.3% from RMB 1,288,755,013.77[19]. - Inventory decreased to RMB 217,162,250.62, a drop of approximately 33.4% from RMB 326,159,533.80[19]. - Total liabilities decreased from ¥1,868,026,362.40 to ¥1,037,050,350.62, a reduction of 44.4%[21]. Shareholder Information - The company has a major shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holding 10.30% of shares, with 21,642,540 shares[15]. - Shanghai Anze Private Fund Management Co., Ltd. holds 5.76% of shares, totaling 12,100,399 shares[15]. - The company repurchased 3,977,700 shares, accounting for 1.89% of the total share capital as of September 30, 2025[16]. - The company has not reported any significant changes in the participation of major shareholders in margin trading or securities lending[16]. Investment Activities - The company reported an investment income of ¥7,343,276.69 in the first three quarters of 2025, compared to a loss of -¥47,577,734.26 in the same period of 2024[24]. - The cash inflow from investment activities totaled CNY 61,047,772.08, an increase of 87.0% from CNY 32,619,956.30 in the previous year[28]. - The net cash flow from investment activities was CNY 36,083,836.68, significantly up from CNY 7,540,032.26 in the same period last year[28]. - The company received CNY 19,285,848.50 from other investment-related cash activities, slightly up from CNY 18,239,609.15 in 2024[28].

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-093 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 | 项 | 目 | 本期发生额（万元） | | --- | --- | --- | | 信用减值损失 | 应收票据坏账损失 | 0.23 | | | 应收账款坏账损失 | 1,742.49 | | | 其他应收款坏账损失 | 328.58 | | 资产减值损失 | 存货跌价损失 | 76.08 | | 合 | 计 | 2,147.38 | 二、本次计提资产减值准备的相关说明 （一）计提信用减值损失的情况说明 根据《企业会计准则》和公司会计政策相关规定，以预期信用损失为基础， 对各类金融资产按照其适用的预期信用损失计量方法计提减值损失。对信用风险 显著不同的金融资产单项评价信用风险，除了单项评估的金融资产外，公司基于 共同风险特征将金融资产划分为不同的组别，参考历史信用损失经验，结合当前 状况并考虑前瞻性信息，在组合的基础上评估信用风险。 （二） ...

Core Viewpoint - The company reported a significant decline in revenue and incurred net losses in the third quarter and the first three quarters of the year [1] Financial Performance - The company's revenue for the third quarter was 274 million yuan, representing a year-on-year decrease of 38.41% [1] - The net loss for the third quarter amounted to 31.12 million yuan [1] - For the first three quarters, the total revenue was 857 million yuan, reflecting a year-on-year decline of 39.64% [1] - The net loss for the first three quarters reached 87.24 million yuan [1]

Market Overview - The pharmaceutical commercial sector increased by 0.32% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Jianfa Zhixin (301584) closed at 39.29, up 10.18% with a trading volume of 315,400 shares and a transaction value of 1.142 billion [1] - Run Da Medical (603108) closed at 15.30, up 3.66% with a trading volume of 180,900 shares and a transaction value of 274 million [1] - Other notable performers include Huaren Health (301408) up 2.28%, and Saili Medical (603716) up 1.98% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 6.1445 million from institutional investors, while retail investors saw a net inflow of 56.1279 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors increased their positions [2] Individual Stock Capital Flow - Run Da Medical saw a significant net outflow of 49.9539 million from institutional investors, indicating a bearish sentiment [3] - Conversely, Jiuzhoutong (866000) had a net inflow of 16.7641 million from institutional investors, suggesting positive interest [3] - Other stocks like Nanjing Medical (600713) and Huaren Health (301408) also showed varying degrees of net inflows and outflows from different investor categories [3]